Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00916149 · ClinicalTrials.gov registry record · NA

Cognitive Effects of Treatment of Interictal Discharges

A NA study of Epilepsy, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00916149: Completed NA study of Epilepsy, sponsored by Massachusetts General Hospital.

NCT00916149 is a NA study of Epilepsy that has completed, run by Massachusetts General Hospital. The registered enrollment target is 31 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00916149, a NA study of Epilepsy, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if levetiracetam (for patients with focal seizures) or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal discharges. The study investigates the possible correlation between reduction of interictal discharges and improved cognitive performance.

Primary Outcome

This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.

Conditions Studied

Interventions

  • DRUG Lamotrigine
  • DRUG levetiracetam

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2007-01
Est. Completion 2012-10
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT00916149 record still lists

NCT00916149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Lamotrigine is the first listed.

NCT00916149 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00916149 about?

NCT00916149 is a clinical study titled "Cognitive Effects of Treatment of Interictal Discharges". The purpose of this study is to determine if levetiracetam (for patients with focal seizures) or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal discharges. The study investigates the possible correlation between reduction of interictal discharges and improv...

What is the current status of trial NCT00916149?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2007-01. Estimated completion is 2012-10.

What conditions does trial NCT00916149 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT00916149?

The interventions under investigation include: Lamotrigine (DRUG), levetiracetam (DRUG).

Who is sponsoring clinical trial NCT00916149?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00916149 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00916149's enrollment target sits among peer trials

31 107th of 160 higher than 53 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00916149, the US trial registry maintained by the National Library of Medicine. NCT00916149 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.